Citi upgraded Glaukos (GKOS) to Buy from Neutral with a price target of $162, up from $132. Glaukos appears to have successfully launched iDose, and it is now executing on its broader portfolio, the analyst tells investors in a research note. With iDose sales likely inflecting next year along with a steady cadence of catalysts, Citi upgraded the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: